AUSTRALIA Trends and Developments Contributed by: Suzy Madar, Matthew Swinn, Kate Hay and Scott Bouvier, Mallesons
Cell and gene therapies, mRNA platforms, antibody- drug conjugates and other advanced modalities are moving steadily from experimentation to clinical and commercial reality. Australia remains an attractive jurisdiction for early-phase clinical trials, supported by deep clinical research expertise, a diverse patient population, a responsive regulator and infrastructure that enables rapid trial initiation, as well as seasonal alignment advantages for global development pro- grammes. However, legal and regulatory complex- ity intensifies as products approach registration and commercialisation. Manufacturing consistency, sup- ply-chain resilience, long-term safety monitoring and post-market obligations are particularly challenging for therapies that are personalised, potentially cura- tive or administered once, and where risks may only emerge over extended time periods. Artificial intelligence (AI) is a driving force across this landscape. AI tools are increasingly embedded in drug discovery, trial design, patient stratification, diagnostics and pharmacovigilance. In 2026, regula- tory attention is focused less on whether AI may be used and more on how it is governed. Issues such as model validation, bias, explainability, human oversight and data provenance now directly inform regulatory approvals, contractual risk allocation, and potential regulatory and civil exposure, particularly where auto- mated outputs influence decision-making in clinical settings. Digital therapeutics and software-as-a-medical- device (SaMD) further strain traditional regulatory environments. Products that combine software, data analytics and therapeutic intent often sit uncomfort- ably within the existing regulatory framework that applies to medicines, medical devices and health ser- vices, with material consequences for classification, evidence thresholds, commercialisation pathways and post-market obligations. Sponsors increasingly need to navigate overlapping regulatory regimes, consum- er protection requirements and privacy obligations in areas where regulatory guidance continues to evolve behind the science. From a commercial perspective, convergence between pharmaceuticals, medical technology and digital plat- forms is also reshaping collaboration models. Joint
ventures and strategic partnerships between biotech- nology companies, device manufacturers, technology firms and data providers are becoming more common. These arrangements require careful alignment of intel- lectual property rights, data ownership, governance structures and exit mechanisms, while ensuring that regulatory accountability remains clear across devel- opment, deployment and ongoing operations. Health Services, Funding and Access: Pressure on Traditional Models Australia’s healthcare system in 2026 faces sustained pressure from rising demand, workforce constraints and fiscal limits, particularly in primary care, aged care and mental health services. These pressures are accelerating experimentation with new service deliv- ery and funding models, particularly where technology promises improved access, workforce substitution or efficiency gains, rather than incremental expansion of existing capacity. Telehealth and virtual care have become entrenched components of healthcare delivery. Between 2020 and 2022, more than 118 million telehealth consultations were conducted across Australia (Australian Digi- tal Health Agency , January 2026), with insurers and employers increasingly incorporating virtual care into standard offerings. While this has materially improved access – particularly for rural and remote popula- tions – it has also exposed regulatory gaps around cross-jurisdictional practice, data security and clinical accountability where care is delivered across multiple platforms and providers. Funding and reimbursement remain central potential fault lines. Although government initiatives continue to support the Medicare system with a recent spike in bulk billing rates, this follows a steady decline, as rising out-of-pocket costs are reshaping consumer behaviour. Private health insurance premiums have increased faster than wage growth, and a growing proportion of patients rely on private or self-funded care for services that were previously delivered within the public system. These dynamics are altering reve- nue flows and risk allocation across the sector, placing pressure on traditional provider models and increasing exposure to complaints, consumer law scrutiny and
27 CHAMBERS.COM
Powered by FlippingBook